1.

Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.

2.

Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.

1.

Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BelSACI).

1.

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium.

2.

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium.

1.

Real-life experience of familial fibrosis in a Belgian university

1.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

2.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

3.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

4.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

5.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

6.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

7.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

8.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

9.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

1.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

2.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

3.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

1.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry

1.

Follow-up of functional exercise capacity in patients with COVID-19: It is improved by telerehabilitation.

2.

Follow-up of functional exercise capacity in patients with COVID-19: It is improved by telerehabilitation.

3.

Follow-up of functional exercise capacity in patients with COVID-19: It is improved by telerehabilitation.

4.

Follow-up of functional exercise capacity in patients with COVID-19: It is improved by telerehabilitation.

5.

Follow-up of functional exercise capacity in patients with COVID-19: It is improved by telerehabilitation.